Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 6
2004 3
2005 5
2006 7
2007 5
2008 4
2009 3
2010 6
2011 5
2012 4
2013 6
2014 9
2015 6
2016 11
2017 10
2018 14
2019 15
2020 17
2021 22
2022 17
2023 16
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

182 results

Results by year

Filters applied: . Clear all
Page 1
Acute exacerbation predicting poor outcomes in idiopathic interstitial pneumonia and advanced lung cancer patients undergoing cytotoxic chemotherapy.
Miyamoto A, Michimae H, Nakahara Y, Akagawa S, Nakagawa K, Minegishi Y, Ogura T, Hontsu S, Date H, Takahashi K, Homma S, Kishi K; Investigators Group for Lung Cancer and IIP. Miyamoto A, et al. Among authors: kishi k. Sci Rep. 2024 May 3;14(1):10162. doi: 10.1038/s41598-024-60833-w. Sci Rep. 2024. PMID: 38702426
Japanese guidelines for the treatment of idiopathic pulmonary fibrosis 2023:Revised edition.
Bando M, Homma S, Date H, Kishi K, Yamauchi H, Sakamoto S, Miyamoto A, Goto Y, Nakayama T, Azuma A, Kondoh Y, Johkoh T, Nishioka Y, Fukuoka J, Miyazaki Y, Yoshino I, Suda T; Ministry of Health, Labour and Welfare, the Study Group on Diffuse Pulmonary Disorders, Scientific Research/Research on Intractable Diseases, and Japanese Respiratory Society. Bando M, et al. Among authors: kishi k. Respir Investig. 2024 May;62(3):402-418. doi: 10.1016/j.resinv.2024.02.014. Epub 2024 Mar 14. Respir Investig. 2024. PMID: 38484504
BRCA2-positive lung adenocarcinoma treated with olaparib: A case report.
Motohashi T, Isobe K, Yoshizawa T, Usui Y, Shimizu H, Sekiya M, Miyoshi S, Nakamura Y, Urabe N, Sakamoto S, Homma S, Sadamoto S, Tochigi N, Kishi K. Motohashi T, et al. Among authors: kishi k. Respirol Case Rep. 2024 Mar 7;12(3):e01317. doi: 10.1002/rcr2.1317. eCollection 2024 Mar. Respirol Case Rep. 2024. PMID: 38455501 Free PMC article.
Immune checkpoint inhibitors in patients with lung cancer having chronic interstitial pneumonia.
Isobe K, Nakamura Y, Sakamoto S, Tomii K, Takimoto T, Miyazaki Y, Matsumoto M, Sugino K, Ichikado K, Moriguchi S, Yamaguchi K, Baba T, Ozasa H, Igata F, Anabuki K, Homma S, Date H, Suda T, Kishi K. Isobe K, et al. Among authors: kishi k. ERJ Open Res. 2024 Mar 4;10(2):00981-2023. doi: 10.1183/23120541.00981-2023. eCollection 2024 Mar. ERJ Open Res. 2024. PMID: 38444654 Free PMC article.
Intrinsic clarithromycin heteroresistance in Mycobacterium avium.
Ito A, Nanjo Y, Kajiwara C, Shiozawa A, Urabe N, Homma S, Kishi K, Yamada K, Ishii Y, Tateda K. Ito A, et al. Among authors: kishi k. J Infect Chemother. 2024 Feb 16:S1341-321X(24)00051-5. doi: 10.1016/j.jiac.2024.02.016. Online ahead of print. J Infect Chemother. 2024. PMID: 38369123
First-line nivolumab plus ipilimumab with or without chemotherapy for Japanese patients with non-small cell lung cancer: LIGHT-NING study.
Imai H, Kijima T, Azuma K, Kishi K, Saito H, Yamaguchi T, Tanizaki J, Yoneshima Y, Fujita K, Watanabe S, Kitazono S, Fukuhara T, Hataji O, Toi Y, Mizutani H, Hamakawa Y, Maemondo M, Ohsugi T, Suzuki K, Horinouchi H, Ohe Y. Imai H, et al. Among authors: kishi k. Jpn J Clin Oncol. 2024 Apr 6;54(4):452-462. doi: 10.1093/jjco/hyad195. Jpn J Clin Oncol. 2024. PMID: 38271158 Free PMC article.
182 results